NASDAQ:CTOR Citius Oncology (CTOR) Stock Price, News & Analysis $0.78 -0.01 (-1.24%) Closing price 06/2/2026 04:00 PM EasternExtended Trading$0.78 +0.00 (+0.19%) As of 06/2/2026 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Citius Oncology Stock (NASDAQ:CTOR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Citius Oncology alerts:Sign Up Key Stats Today's Range$0.77▼$0.8150-Day Range$0.49▼$0.9952-Week Range$0.49▼$6.19Volume29,081 shsAverage Volume78,193 shsMarket Capitalization$72.76 millionP/E RatioN/ADividend YieldN/APrice Target$6.00Consensus RatingHold Company Overview Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ. Read More Citius Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreCTOR MarketRank™: Citius Oncology scored higher than 47% of companies evaluated by MarketBeat, and ranked 615th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingCitius Oncology has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCitius Oncology has a consensus price target of $6.00, representing about 666.8% upside from its current price of $0.78.Amount of Analyst CoverageCitius Oncology has received no research coverage in the past 90 days.Read more about Citius Oncology's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Citius Oncology is -1.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Citius Oncology is -1.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCitius Oncology has a P/B Ratio of 1.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Citius Oncology's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.56% of the float of Citius Oncology has been sold short.Short Interest Ratio / Days to CoverCitius Oncology has a short interest ratio ("days to cover") of 4.47.Change versus previous monthShort interest in Citius Oncology has recently decreased by 26.07%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCitius Oncology does not currently pay a dividend.Dividend GrowthCitius Oncology does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.47 News SentimentCitius Oncology has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Citius Oncology this week, compared to 2 articles on an average week.MarketBeat Follows3 people have added Citius Oncology to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Citius Oncology insiders have not sold or bought any company stock.Percentage Held by Insiders7.80% of the stock of Citius Oncology is held by insiders.Percentage Held by Institutions70.52% of the stock of Citius Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Citius Oncology's insider trading history. Receive CTOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Citius Oncology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CTOR Stock News HeadlinesCitius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory ...June 1 at 12:44 PM | finance.yahoo.comCitius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic MalignanciesJune 1 at 7:00 AM | prnewswire.comTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free. | Reagan Gold Group (Ad)Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual MeetingMay 26, 2026 | prnewswire.comCitius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business UpdateMay 15, 2026 | prnewswire.comCitius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business UpdateMay 15, 2026 | prnewswire.comCitius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® CommercializationMay 5, 2026 | prnewswire.comCitius Oncology Ships First International Order of LYMPHIR™ to EuropeApril 29, 2026 | prnewswire.comSee More Headlines CTOR Stock Analysis - Frequently Asked Questions How have CTOR shares performed this year? Citius Oncology's stock was trading at $1.00 at the start of the year. Since then, CTOR shares have decreased by 21.8% and is now trading at $0.7825. How were Citius Oncology's earnings last quarter? Citius Oncology, Inc. (NASDAQ:CTOR) posted its quarterly earnings data on Friday, May, 15th. The company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by $0.26. The company had revenue of $1.67 million for the quarter, compared to the consensus estimate of $7 million. Who are Citius Oncology's major shareholders? Top institutional shareholders of Citius Oncology include Bank of America Corp DE (4.34%). How do I buy shares of Citius Oncology? Shares of CTOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Citius Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Citius Oncology investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Advanced Micro Devices (AMD), Broadcom (AVGO), Confluent (CFLT), Genius Sports (GENI) and Intel (INTC). Company Calendar Last Earnings5/15/2026Today6/02/2026Next Earnings (Estimated)8/18/2026Fiscal Year End9/30/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 CTOR's financial health is in the Green zone, according to TradeSmith. CTOR has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CTOR Previous SymbolNASDAQ:CTOR CIK1851484 Webwww.citiusonc.com Phone347-627-0058FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Citius Oncology$6.00 High Price Target$6.00 Low Price Target$6.00 Potential Upside/Downside+666.8%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$24.76 million Net MarginsN/A Pretax Margin-747.62% Return on Equity-99.47% Return on Assets-42.16% Debt Debt-to-Equity Ratio0.11 Current Ratio0.50 Quick Ratio0.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.54 per share Price / Book1.45Miscellaneous Outstanding Shares92,980,000Free Float85,728,000Market Cap$72.76 million OptionableN/A Beta3.41 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:CTOR) was last updated on 6/3/2026 by MarketBeat.com Staff. From Our PartnersYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...Brownstone Research | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredElon’s AI supercomputer just went live. Here’s my #1 stock.Is Elon about to trigger another 315X opportunity? Elon gave Tesla investors the chance to make more than 3...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
